Download presentation
Presentation is loading. Please wait.
Published bySurya Kurniawan Modified over 5 years ago
1
Pseudomonas aeruginosa 136 (15.4%) 70 (19.2%) 66 (12.7%) 0.009
Table 1. Seven main organisms isolated from SSI according to the type of SSI No. of strains (%) P-value Total Incisional SSI Organ space SSI Enterobacteriaceae* 304 (34.4%) 96 (26.3%) 208 (40.2%) <0.001 Pseudomonas aeruginosa 136 (15.4%) 70 (19.2%) 66 (12.7%) 0.009 Staphylococcus aureus [MRSA] 160 (18.1%) [86, 9.7%] 82 (22.5%) [40, 11.0%] 78 (15.1%) [46, 8.9%] 0.005 [0.305] Enterococcus faecalis 170 (19.3%) 73 (20.0%) 97 (18.7%) 0.636 Bacteroides fragilis group 113 (12.8%) 44 (12.1%) 69 (13.3%) 0.579 883 (100.0%) 365 (100.0%) 518 (100.0%) ― *:E. coli (n=152), E. cloacae (n=96), K. pneumoniae (n=56)
2
Table 2. Main organisms isolated from surgical site infection (SSI) according to the type of procedure in the surveillance conducted between and 2015 Main organisms isolated from SSI Type of procedure Surgery for lower intestinal tract Surgery for stomach and esophagus Surgery for hepatobiliary-pancreas Other abdominal surgery Procedures except for abdominal surgery Total Enterobacteriaceae 148 38 97 6 15 304 (34.4%) Pseudomonas aeruginosa 65 26 33 4 8 136 (15.4%) Staphylococcus aureus [MRSA] 55[35] 14 [6] 46 [24] 4 [2] 42 [20] 160 (18.1%) [86, 9.7%] Enterococcus faecalis 90 61 2 170 (19.3%) Bacteroides fragilis group 91 13 1 113 (12.8%) 446 101 250 17 69 883 (100%)
3
ESBL producing organisms CPE* CRE** except for CPE
Table 3. Comparison of the incidence of antibiotic resistant Enterobacteriaceae between 2010 and 2014–15 ESBL producing organisms CPE* CRE** except for CPE 2010 Echerichia coli 9/95 (9.5%) 35/152 (23.0%) Klebsiella pneumoniae 0/53(0%) 6/56 (10.7%) 1 (1.9%) 1 (1.8%) Enterobacter cloacae 0/58(0%) 0/96 (0%) (1.7%) 1 (1.0%) 12 (20.7%) 25 (26.0%) Total 11/206 (5.3%) 41/304 (13.5%) 2 (1.0%) 2 (0.7%) (5.8%) 25 (8.2%) E. coli (n=152) K. pneumoniae (n=56) E. cloacae (n=95) *: carbapenemase producing Enterobacteriaceae, ***: notification criteria of carbapenem resistant Enterobacteriaceae (CRE) defined by Ministry of Health, labour and Welfare in Japan
4
Geometric standard deviation
Table 4. Change of antibiotic susceptibility distribution in MRSA between 2010 and Anti-microbial agent year MIC (μg/mL) Geometric mean MIC (μg/mL) Geometric standard deviation 95% CI P-value ≤0.063 0.125 0.25 0.5 1 2 4 8 16 ≥32 VCM 2010 91 10 1.055 1.261 -0.177, 0.585 0.292 19 65 0.851 1.392 TEIC 3 44 39 15 0.823 1.853 -0.533, 0.530 0.996 36 6 0.824 1.836 ABK 57 35 0.659 1.676 -0.331, 0.665 0.510 23 43 1 0.492 1.790 LZD 25 74 1.736 1.407 -0.502, 0.284 0.586 9 75 1.845 1.309 DAP 56 0.352 1.490 -0.460, 0.417 0.922 40 0.374 1.559 TGC Not performed - 27 13 18 28 0.365 2.367 Shaded column indicate the susceptive range; 95% CI: 95% confidence interval
5
Table 5. Comparison of antibiotic susceptibility distribution in Gram-negative organisms between the surveillance studies conducted in 2010 and 2014–15 Antimicrobial agents Susceptible rate (%) E. coli K. pneumoniae E. cloacae P. aeruginosa 2010 (n=95) 2014–15 (n=152) (n=53) (n=56) (n=58) (n=108) (n=136) SBT/ABPC 56.8 69.7 88.7 - TAZ/PIPC* 95.8 95.4 96.2 98.2 81.0 83.3 92.6 93.4 CEZ 52.6 63.2 81.1 83.9 CMZ 97.4 94.3 94.6 0.0 - CAZ 89.5 92.1 98.1 96.4 74.1 68.8 89.8 94.1 CFPM 96.8 80.3 100.0 92.9 92.7 91.7 95.6 MEPM 97.9 93.5 91.9 IPM 71.9 88.0 84.6 AZT 87.4 82.2 77.6 86.1 89.7 GM 90.5 99.3 CPFX 73.7 73.0 91.1 93.8 *: Susceptibility testing with a fixed concentration of 4 µg/mL TAZ
6
Geometric standard deviation
Table 6. Antibiotic susceptibility distribution in extended-spectrum β-lactamase-producing Enterobacteriaceae Anti-microbial agent MIC (μg/mL), n=41 Susceptibility rate Geometric mean MIC (μg/mL) Geometric standard deviation ≤0.063 0.125 0.25 0.5 1 2 4 8 16 32 64 128 ≥ 256 MEPM 38 100% 0.065 1.165 TAZ/PIPC* 14 3 1 - 9.514 2.857 TAZ/PIPC** 5 20 92.5% 2.979 3.132 CMZ 1.741*** 3.972 CFX 11 15 6 80.0 % 6.169 3.603 FMOX 27 - 0.149**** 7.271 GM 75.0% 1.5516 6.785 CPFX 13 7 27.5% 8.877 12.661 STFX 9 17 0.500***** 3.964 n=41, E. coli 35株, K. pneumoniae 6株. 1例 メタロβラクタマーゼ産生 MEPM 0.071 TAZ/PIPC 9.514 CMZ 1.932 FMOX 0.169 GM 1.569 CPFX 7.601 Shaded column indicate the susceptive rang; one strain that produced carbapenemase was excluded. *: concentration of TAZ was changed according to the concentration ratio of 1 : 8; **: a fixed concentration of 4 µg/mL TAZ was used; ***; vs. CFX, P<0.001; ****: vs. CFX, p<0.001, CMZ, P=0.228; *****: vs. CPFX, P<0.001
7
No. of Antibiotic resistant organisms in P. aeruginosa*
Table 7.Comparison of isolation rates for antibiotic-resistant Pseudomonas aeruginosa between the surveillance studies conducted in 2010 and 2014–2015 Antibiotic resistant organisms in P. aeruginosa* No. of Antibiotic resistant organisms in P. aeruginosa* 2010, n=108 2014–2015, n=136 Resistance to at least one class of antibiotics 12 (11.1%) 12 (8.8%) Resistance to at least two classes of antibiotics 6 (5.6%) 6 (4.4%) Resistance to at least three class of antibiotics 2 (1.9%) 4 (2.9%) *: P.aeruginosa resistant to any of the following: MEPM; TAZ/PIPC; CFPM; CPFX and GM
8
Geometric standard deviation
Table 8.Antibiotic susceptibility distribution for Bacteroides fragilis group species Anti-microbial agent MIC (μg/mL), n=113 Susceptible rate Geometric mean MIC (μg/mL) Geometric standard deviation ≤0.063 0.125 0.25 0.5 1 2 4 8 16 32 64 128 ≥256 SBT/ABPC 13 21 15 17 23 18 79.6% 3.452 3.602 TAZ/PIPC* 1 0 22 31 12 3 - 7.297 3.139 TAZ/PIPC ** 6 20 9 11 5 97.3% 1.791 6.865 CMZ 10 14 28 7 49.6% 21.347 2.814 CFX 66.4% 16.000*** 2.770 FMOX 10.100**** 9.157 MEPM 94.7% 0.462 4.196 CPFX 19 33 21.743 3.286 MFLX 26 61.9% 2.360***** 3.807 STFX 29 0.276****** 3.451 CLDM 53 46.9% 10.543 24.140 TGC 35 27 0.384 2.762 MNZ 57 38 100% 1.152 1.785 Shaded column indicate the susceptive range; MIC: minimum inhibitory concentration; *: concentration of TAZ was changed according to the concentration ratio of 1 : 8; **: a fixed concentration of 4 µg/mL TAZ was used; ***: vs. CMZ, P<0.001; ****: vs. CMZ, CFX, P<0.001; *****: vs. CPFX, P<0.001; ******: vs. CPFX, MFLX, P<0.001
9
Table 9. Comparison of susceptibility rates for Bacteroides fragilis and non-fragilis Bacteroides species identified in the surveillance study conducted in 2014–15 Anti-microbial agent Susceptible rate P-value Bacteroides fragils (n=53) Non-fragilis Bacteroides (n=60) Bacteroides thetaiotaomicron (n=26) Other non-fragilis Bacteroides (n=34) SBT/ABPC 88.7 71.7 0.045 73.1 70.6 0.832 TAZ/PIPC* 94.3% 100% 0.200 100% ― CMZ 79.2% 23.3% <0.001 3.8% 38.2% 0.005 CFX 86.8% 48.3% 19.2% 70.6% MEPM 88.7% 0.024 MFLX 67.9% 56.7% 0.219 61.5% 52.9% 0.505 CLDM 60.4% 35.0% 0.007 47.1% 0.049 TGC ― 0.950 MNZ 100% *: a fixed concentration of 4 µg/mL TAZ was used
10
Electronic data Supplementary Table 1
Electronic data Supplementary Table 1. Antibiotic susceptibility rates for methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant S. aureus (MRSA), and Enterococcus faecalis Organism (number tested) and antimicrobial agent MIC (μg/mL) % MIC50 MIC90 Range Susceptible Intermediate Resistant MSSA (74) MPIPC 0.25 0.5 100.0% 0.0% ABPC 2 ≤0.06-8 ― SBT/ABPC 1 ≤0.06-2 PIPC 4 0.5-8 TAZ/PIPC* 0.5-4 TAZ/PIPC** CEZ CAZ 8 4-16 CFPM 1-8 CMZ 0.25-2 CFX 2-4 FMOX IPM ≤0.06 ≤ PAPM 0.125 MEPM ≤ BIPM DRPM CPFX 16 0.125-≥256 81.1% 2.7% 16.2% LVFX ≤0.06-≥256 83.8% PZFX MFLX ≤ 1.3% 14.9% STFX ≤ GM 32 AMK 1-64 98.6% 1.4% ABK EM ≥256 0.25-≥256 82.4% CLDM 97.3% MINO TGC VCM 0.5-1 TEIC DAP LZD 1-4 ST 0.063 RFP
11
Electronic data Supplementary Table 1. continued
Organism (number tested) and antimicrobial agent MIC (μg/mL) % MIC50 MIC90 Range Susceptible Intermediate Resistant MRSA (86) MPIPC 128 ≥256 1-≥256 ― CFX 64 0.125-≥256 IPM 2 32 <0.06-≥128 ABK 0.5 1 EM 0.25-≥256 11.6% 0.0% 88.4% CLDM 27.9% 1.2% 70.9% MINO 8 16 ≤ 41.9% 8.1% 50.0% TGC VCM 0.25-2 100.0% TEIC DAP LZD 0.5-4 ST 0.063 0.125 REF ≤0.06 ≤0.06-4 98.8%
12
Electronic data Supplementary Table 1. continued
Organism (number tested) and antimicrobial agent MIC (μg/mL) % MIC50 MIC90 Range Susceptible Intermediate Resistant E. faecalis (170) ABPC 1 2 0.5-8 100.0% 0.0% PIPC 4 2-32 ― TAZ/PIPC* TAZ/PIPC** IPM 0.25-4 PAPM 0.5-4 MEPM 8 1-16 BIPM DRPM 1-8 CPFX 75.9% 14.7% 9.4% LVFX 0.5-≥256 90.6% 0.6% 8.8% PZFX 1-≥256 MFLX 0.5 STFX 0.125 ≤0.06-4 TGC 0.25 ≤ VCM 0.5-2 TEIC DAP 0.25-8 98.8% 1.2% LZD 1-4 88.2% 11.8% *: concentration of TAZ was changed according to the concentration ratio of 1 : 8; **: a fixed concentration of 4 µg/mL TAZ was used
13
Electronic data Supplementary Table 2
Electronic data Supplementary Table 2. Antibiotic susceptibility of Enterobacteriaceae species Organism (number tested) and antimicrobial agent MIC (μg/mL) % MIC50 MIC90 Range Susceptible Intermediate Resistant E. coli (152) ABPC 4 ≥256 1-≥256 55.3% 1.9% 42.8% SBT/ABPC 32 1-≥128 69.7% 16.5% 13.8% PIPC 2 0.5-≥256 61.2% 4.6% 34.2% TAZ/PIPC* 16 ≤ ― TAZ/PIPC** 95.4% 3.3% 1.3% CEZ 1 ≤0.06-≥256 63.2% 3.9% 32.9% CAZ 0.125 ≤0.06-≥128 92.1% 2.0% 5.9% CFPM ≤0.06 8 80.3% 13.1% 6.6% CMZ 0.5 97.4% 0.6% CFX 89.5% FMOX 0.25 S/C ≤ IPM ≤0.06-1 100.0% 0.0% PAPM ≤ MEPM ≤ BIPM DRPM AZT 82.2% 11.2% CPFX 64 73.0% 27.0% LVFX 25.7% PZFX ≤ MFLX STFX ≤0.06-4 GM 9.2% AMK 1-32 99.3% 0.7% TGC FOM
14
Electronic data Supplementary Table 2. continued
Organism (number tested) and antimicrobial agent MIC (μg/mL) % MIC50 MIC90 Range Susceptible Intermediate Resistant K. pneumoniae (56) PIPC 4 ≥256 1-≥256 83.9% 1.8% 14.3% TAZ/PIPC* 16 ≤ TAZ/PIPC** 2 8 0.5-32 98.2% 0.0% CEZ 1 ≤0.06-≥256 16.1% CAZ 0.125 0.5 96.4% 3.6% CFPM ≤0.06 ≤ 92.9% 3.5% CMZ 94.6% CFX 91.1% 5.4% FMOX ― S/C ≤ IPM 0.25 PAPM ≤0.06-4 MEPM ≤0.06-2 BIPM DRPM AZT ≤ CPFX LVFX PZFX ≤0.06-8 MFLX STFX GM AMK 0.5-8 100.0% TGC 0.25-4 FOM 32 2-≥256
15
Electronic data Supplementary Table 2. continued
Organism (number tested) and antimicrobial agent MIC (μg/mL) % MIC50 MIC90 Range Susceptible Intermediate Resistant E. cloacae (96) PIPC 4 128 ≤0.06-≥256 76.0% 9.4% 14.6% TAZ/PIPC* 64 ≤ ― TAZ/PIPC** 2 83.3% 8.4% 8.3% CAZ 0.5 0.125-≥128 68.8% 4.1% 27.1% CFPM ≤0.06 1 ≤ 92.7% 4.2% 3.1% S/C 16 IPM 0.25-4 71.9% 1.0% PAPM MEPM 0.125 ≤0.06-2 97.9% 2.1% 0.0% BIPM 0.25 DRPM ≤0.06-4 1.1% AZT 32 24.0% CPFX ≤ 93.8% 2.0% LVFX 94.8% PZFX ≤0.06-8 MFLX ≤ STFX GM 0.25-≥256 AMK 0.5-64 99.0% TGC 0.25-8 FOM 1-≥256 89.6% 6.2% *: concentration of TAZ was changed according to the concentration ratio of 1 : 8; **: a fixed concentration of 4 µg/mL TAZ was used
16
Electronic data Supplementary Table 3
Electronic data Supplementary Table 3. Antibiotic susceptibility of Pseudomonas aeruginosa Organism (number tested) and antimicrobial agent MIC (μg/mL) % MIC50 MIC90 Range Susceptible Intermediate Resistant P. aeruginosa (136) PIPC 4 16 ≤0.06-≥256 91.9% 5.2% 2.9% TAZ/PIPC* ― TAZ/PIPC** 93.4% 3.7% CAZ 2 ≤ 94.1% 3.0% CFPM 95.6% 0.7% S/C IPM 8 84.6% 12.5% PAPM ≤ MEPM 0.5 5.1% BIPM ≤ DRPM 0.25 92.6% 4.5% AZT 89.7% CPFX 1 1.5% 5.9% LVFX 0.8% 6.6% PZFX MFLX STFX 0.125 ≤0.06-4 GM 99.3% 0.0% AMK 0.25-8 100.0% ABK FOM 32 128 2-≥256 *: concentration of TAZ was changed according to the concentration ratio of 1 : 8; **: a fixed concentration of 4 µg/mL TAZ was used
17
Electronic data Supplementary Table 4
Electronic data Supplementary Table 4. Antibiotic susceptibility of Bacteroides fragilis group species Organism (number tested) and antimicrobial agent MIC (μg/mL) % MIC50 MIC90 Range Susceptible Intermediate Resistant B. fragilis (53) ABPC 128 ≥256 0.5-≥256 1.9% 0.0% 98.1% SBT/ABPC 2 16 0.25-≥128 ― PIPC 32 1-≥256 50.9% 9.5% 39.6% TAZ/PIPC* 4 TAZ/PIPC** 0.5 ≤0.06-≥256 94.3% 5.7% CAZ 64 ≥128 2-≥128 CFPM 2-≥256 CMZ 8 4-128 79.2% 11.4% 9.4% CFX 4-≥256 86.8% 3.8% FMOX 0.25-≥256 S/C IPM 0.25 ≤0.06-≥128 PAPM MEPM 88.7% 7.5% BIPM 1 0.125-≥256 DRPM 0.125-≥128 11.3% CPFX LVFX 1-128 PZFX MFLX 67.9% 7.6% 24.5% STFX 0.125 ≤0.06-4 CLDM 60.4% MINO ≤ TGC MNZ 0.25-4 100.0%
18
Electronic data Supplementary Table 4. continued
Organism (number tested) and antimicrobial agent MIC (μg/mL) % MIC50 MIC90 Range Susceptible Intermediate Resistant B. thetaiotaomicron (26) ABPC ≥256 8-≥256 0.0% 100.0% SBT/ABPC 8 16 1-16 ― PIPC 16-≥256 30.8% 3.8% 65.4% TAZ/PIPC* 32 8-32 TAZ/PIPC** 0.5-32 CAZ ≥128 CFPM CMZ 64 128 16-128 23.1% 73.1% CFX 19.2% 53.9% 26.9% FMOX 4-≥256 S/C 2-16 IPM 0.5 2 96.2% PAPM 4 MEPM BIPM 0.25-4 DRPM CPFX LVFX 4-128 PZFX MFLX 1-32 61.5% 27.0% 11.5% STFX CLDM 0.25-≥256 11.6% 69.2% MINO ≤0.06-4 TGC 0.25 ≤0.06-2 MNZ 0.5-4
19
Electronic data Supplementary Table 4. continued
Organism (number tested) and antimicrobial agent MIC (μg/mL) % MIC50 MIC90 Range Susceptible Intermediate Resistant other Bacteroides spp. (34) ABPC ≥256 4-≥256 0.0% 0.0% 100.0% SBT/ABPC 8 16 1-32 ― PIPC 128 32.4% 11.7% 55.9% TAZ/PIPC* 32 2-64 TAZ/PIPC** 4 ≤ 100.0% CAZ ≥128 16-≥128 CFPM 8-≥256 CMZ 64 4-128 38.2% 29.4% CFX 2-128 70.6% 20.6% 8.8% FMOX 0.5-≥256 S/C 2-16 IPM 0.5 2 PAPM 1 ≤0.06-8 MEPM BIPM DRPM 0.25-2 CPFX LVFX 1-128 PZFX 2-≥256 MFLX 52.9% 8.9% STFX 0.25 ≤0.06-4 CLDM ≤0.06-≥256 47.1% 5.8% MINO TGC ≤0.06-2 MNZ *: concentration of TAZ was changed according to the concentration ratio of 1 : 8; **: a fixed concentration of 4 µg/mL TAZ was used
20
Electronic supplementary Table 5
Electronic supplementary Table 5. Antibiotic susceptibility in organisms isolated from organ/space SSI in the surveillance conducted between 2014 and 2015 Organism (number tested) and antimicrobial agent MIC (μg/mL) % MIC 50 MIC 90 Susceptible Intermediate Resistant E. coli (111) SBT/ABPC 4 32 69.4% 17.1% 13.5% TAZ/PIPC* 2 16 ― TAZ/PIPC** 95.5% 2.7% 1.8% CFPM ≤0.06 8 80.2% 6.3% MEPM 100.0% 0.0% GM 0.5 91.0% 0.9% 8.1% CPFX 72.1% 27.9% LVFX 0.125 26.1% PZFX MFLX STFX 1
21
Electronic supplementary Table 5. continued
Organism (number tested) and antimicrobial agent MIC (μg/mL) % MIC 50 MIC 90 Susceptible Intermediate Resistant K. pneumonia (43) TAZ/PIPC* 4 8 TAZ/PIPC** 2 97.7% 2.3% 0.0% CEZ 1 ≥128 83.7% 16.3% CMZ 0.5 CAZ 0.125 95.3% 4.7% CFPM ≤0.06 90.7% MEPM IPM 0.25 AZT GM CPFX LVFX
22
Electronic supplementary Table 5. continued
Organism (number tested) and antimicrobial agent MIC (μg/mL) % MIC 50 MIC 90 Susceptible Intermediate Resistant E.cloacae (54) TAZ/PIPC* 4 64 TAZ/PIPC** 128 77.8% 7.4% 14.8% CMZ ≥128 0.0% 1.9% 98.1% CAZ 0.5 66.7% 5.6% 27.8% CFPM ≤0.06 88.9% 3.7% MEPM 0.125 IPM 1 2 79.6% 20.4% AZT 32 72.2% 25.9% GM 0.25 100.0% CPFX LVFX 90.7%
23
Electronic supplementary Table 5. continued
Organism (number tested) and antimicrobial agent MIC (μg/mL) % MIC 50 MIC 90 Susceptible Intermediate Resistant P. aeruginosa (66) TAZ/PIPC* 4 16 ― TAZ/PIPC** 90.9% 6.1% 3.0% CAZ 2 92.4% 4.6% CFPM 95.5% 0.0% 4.5% IPM 78.8% 16.7% PAPM 8 32 ― ― MEPM 0.5 89.4% CPFX 0.25 1 1.5% 7.6% LVFX 9.1% PZFX MFLX STFX 0.125 GM 98.5% AMK 100.0%
24
Electronic supplementary Table 5. continued
Organism (number tested) and antimicrobial agent MIC (μg/mL) % MIC50 MIC90 Range Susceptible Intermediate Resistant MSSA (32) ABPC 0.25 2 ≤0.06-2 - SBT/ABPC 0.5 PIPC 1 4 0.5-8 TAZ/PIPC ** 0.5-2 CEZ CAZ 8 4-16 CFPM 1-4 CMZ 1-2 CFX 2-4 100.0% 0.0% FMOX IPM ≤0.06 ≤ MEPM 0.125 ≤ CPFX 93.8% 6.3% LVFX ≤ MFLX ≤0.06-4 GM 90.6% 3.1% AMK 1-64 96.9% ABK EM ≥128 0.25-≥128 81.3% 18.8% CLDM MINO TGC VCM 0.5-1 TEIC DAP LZD ST 0.06 RFP
25
Electronic supplementary Table 5. continued
Organism (number tested) and antimicrobial agent MIC (μg/mL) % MIC50 MIC90 Range Susceptible Intermediate Resistant MRSA (46) ABK 0.5 1 0.25-8 - CLDM ≥128 0.125-≥128 21.7% 2.2% 76.1% MINO 16 ≤ 32.6% 8.7% 58.7% TGC VCM 0.25-2 100.0% 0.0% TEIC 2 0.5-8 DAP 0.25-1 LZD 1-4 ST 0.063 0.125 REF ≤0.06 ≤0.06-4 97.8%
26
Electronic supplementary Table 5. continued
Organism (number tested) and antimicrobial agent MIC (μg/mL) % MIC 50 MIC 90 Susceptible Intermediate Resistant E. faecalis (97) ABPC 1 2 100.0% 0.0% PIPC 4 ― IPM LZD 90.7% 9.3% CPFX 32 76.3% 11.3% 12.4% LVFX 87.6% 1.1% MFLX 0.5 8 STFX 0.125
27
Electronic supplementary Table 5. continued
Organism (number tested) and antimicrobial agent MIC (μg/mL) % MIC 50 MIC 90 Susceptible Intermediate Resistant B. fragilis group (69) SBT/ABPC 4 16 ― TAZ/PIPC* 8 32 TAZ/PIPC** 2 95.7% 0.0% 4.3% CMZ 64 50.7% 17.4% 31.9% CFX 128 65.2% 18.9% 15.9% FMOX MEPM 0.25 94.2% 5.8% CPFX LVFX MFLX 55.1% 29.0% STFX 0.125 CLDM ≥256 44.9% 1.5% 53.6% TGC MNZ 1 100.0% *: concentration of TAZ was changed according to the concentration ratio of 1 : 8; **: a fixed concentration of 4 µg/mL TAZ was used
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.